The relationship between the dynamic trajectory of inflammatory markers in VA-ECMO patients and the 28-day survival rate, as well as mediating causal analysis.

IF 4.8 3区 医学 Q2 CELL BIOLOGY
You Zhou, Zhi Cheng, Liqun Sun, Jiayan Han, Suhui Li, Xin Wang, Leiming Xu
{"title":"The relationship between the dynamic trajectory of inflammatory markers in VA-ECMO patients and the 28-day survival rate, as well as mediating causal analysis.","authors":"You Zhou, Zhi Cheng, Liqun Sun, Jiayan Han, Suhui Li, Xin Wang, Leiming Xu","doi":"10.1007/s00011-025-01999-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a simplified cardiopulmonary bypass device that provides temporary respiratory and circulatory support and adequate recovery time for the heart and lung, but the mortality rate of acute and critically ill patients undergoing VA-ECMO is still high. Progression of systemic inflammatory response is associated with mortality in ECMO patients. The objective of this study was to investigate the dynamic changes of various inflammatory markers and their relationship with 28-day mortality in patients with VA-ECMO.</p><p><strong>Methods: </strong>A retrospective cohort analysis was conducted on 200 patients receiving VA-ECMO treatment evaluating inflammatory markers including neutrophil-to-lymphocyte ratio (NLR), systemic inflammatory response index (SIRI), procalcitonin (PCT), interleukin-6 (IL-6), and C-reactive protein (CRP) at various time points. A dynamic trajectory model was constructed, and survival differences between groups were assessed using Kaplan-Meier plots and log-rank tests. Multiple Cox proportional hazard models were built to analyze the relationship between dynamic trajectories and clinical outcomes. Causal mediation analysis was applied to determine whether changes in inflammatory trajectories mediated survival outcomes in patients on VA-ECMO through other variables.</p><p><strong>Results: </strong>Age, Acute Physiology and Chronic Health Evaluation (APACHE) II score, Lactic acid, PCO2, aspartate aminotransferase (AST) levels, diastolic blood pressure, mean arterial pressure and pH significantly impacted the 28-day survival rate (p < 0.05), with higher mortality observed in patients exhibiting poor inflammatory trajectories.Kaplan-Meier survival analysis revealed that patients in the ascending (AS) group had a significantly higher risk of death than those in the stable (ST) and descending (DS) groups (log-rank p < 0.001). Furthermore, multivariate Cox regression analysis identified IL-6 as the most strongly correlated inflammatory marker with mortality risk [Hazard ratio (HR) = 1.97, 95% confidence interval (CI) 1.35-2.87, p < 0.001].</p><p><strong>Conclusions: </strong>This study highlights the importance of dynamic monitoring of inflammatory biomarkers in patients on VA-ECMO, suggesting that individualized treatment adjustments based on these markers could enhance survival rates. Future research should prioritize larger, multicenter cohort studies and clinical trials to validate these findings, aiming to optimize treatment strategies for patients on VA-ECMO.</p>","PeriodicalId":13550,"journal":{"name":"Inflammation Research","volume":"74 1","pages":"45"},"PeriodicalIF":4.8000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammation Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00011-025-01999-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a simplified cardiopulmonary bypass device that provides temporary respiratory and circulatory support and adequate recovery time for the heart and lung, but the mortality rate of acute and critically ill patients undergoing VA-ECMO is still high. Progression of systemic inflammatory response is associated with mortality in ECMO patients. The objective of this study was to investigate the dynamic changes of various inflammatory markers and their relationship with 28-day mortality in patients with VA-ECMO.

Methods: A retrospective cohort analysis was conducted on 200 patients receiving VA-ECMO treatment evaluating inflammatory markers including neutrophil-to-lymphocyte ratio (NLR), systemic inflammatory response index (SIRI), procalcitonin (PCT), interleukin-6 (IL-6), and C-reactive protein (CRP) at various time points. A dynamic trajectory model was constructed, and survival differences between groups were assessed using Kaplan-Meier plots and log-rank tests. Multiple Cox proportional hazard models were built to analyze the relationship between dynamic trajectories and clinical outcomes. Causal mediation analysis was applied to determine whether changes in inflammatory trajectories mediated survival outcomes in patients on VA-ECMO through other variables.

Results: Age, Acute Physiology and Chronic Health Evaluation (APACHE) II score, Lactic acid, PCO2, aspartate aminotransferase (AST) levels, diastolic blood pressure, mean arterial pressure and pH significantly impacted the 28-day survival rate (p < 0.05), with higher mortality observed in patients exhibiting poor inflammatory trajectories.Kaplan-Meier survival analysis revealed that patients in the ascending (AS) group had a significantly higher risk of death than those in the stable (ST) and descending (DS) groups (log-rank p < 0.001). Furthermore, multivariate Cox regression analysis identified IL-6 as the most strongly correlated inflammatory marker with mortality risk [Hazard ratio (HR) = 1.97, 95% confidence interval (CI) 1.35-2.87, p < 0.001].

Conclusions: This study highlights the importance of dynamic monitoring of inflammatory biomarkers in patients on VA-ECMO, suggesting that individualized treatment adjustments based on these markers could enhance survival rates. Future research should prioritize larger, multicenter cohort studies and clinical trials to validate these findings, aiming to optimize treatment strategies for patients on VA-ECMO.

VA-ECMO患者炎症标志物动态轨迹与28天生存率的关系及中介因果分析。
背景:静脉-动脉体外膜氧合(VA-ECMO)是一种简化的体外循环装置,可为心肺提供暂时的呼吸和循环支持和足够的恢复时间,但急性和危重症患者接受VA-ECMO的死亡率仍然很高。全身炎症反应的进展与ECMO患者的死亡率相关。本研究的目的是探讨VA-ECMO患者各种炎症标志物的动态变化及其与28天死亡率的关系。方法:对200例接受VA-ECMO治疗的患者进行回顾性队列分析,评估不同时间点的炎症标志物,包括中性粒细胞与淋巴细胞比率(NLR)、全身炎症反应指数(SIRI)、降钙素原(PCT)、白细胞介素-6 (IL-6)、c反应蛋白(CRP)。建立动态轨迹模型,采用Kaplan-Meier图和log-rank检验评估组间生存差异。建立多个Cox比例风险模型,分析动态轨迹与临床结果之间的关系。应用因果中介分析来确定炎症轨迹的改变是否通过其他变量介导VA-ECMO患者的生存结局。结果:年龄、急性生理和慢性健康评估(APACHE) II评分、乳酸、PCO2、天冬氨酸转氨酶(AST)水平、舒张压、平均动脉压和pH值显著影响VA-ECMO患者28天生存率(p)。结论:本研究强调了动态监测VA-ECMO患者炎症生物标志物的重要性,提示基于这些标志物的个体化治疗调整可以提高生存率。未来的研究应优先考虑更大规模的多中心队列研究和临床试验,以验证这些发现,旨在优化VA-ECMO患者的治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Inflammation Research
Inflammation Research 医学-免疫学
CiteScore
9.90
自引率
1.50%
发文量
134
审稿时长
3-8 weeks
期刊介绍: Inflammation Research (IR) publishes peer-reviewed papers on all aspects of inflammation and related fields including histopathology, immunological mechanisms, gene expression, mediators, experimental models, clinical investigations and the effect of drugs. Related fields are broadly defined and include for instance, allergy and asthma, shock, pain, joint damage, skin disease as well as clinical trials of relevant drugs.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信